Topics

Sotagliflozin approved to treat type 1 diabetes in Europe

06:09 EDT 1 May 2019 | SmartBrief

The European Commission has approved Sanofi and Lexicon Pharmaceuticals' Zynquista, or sotagliflozin, as treatment for type 1 -More

Original Article: Sotagliflozin approved to treat type 1 diabetes in Europe

NEXT ARTICLE

More From BioPortfolio on "Sotagliflozin approved to treat type 1 diabetes in Europe"

Quick Search

Relevant Topics

Sanofi-Aventis
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...